Tap the Weight-Loss Drug Market With These ETFs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2024
0mins
Source: NASDAQ.COM
Emerging Weight-Loss Drug Market: The weight-loss drug market is expanding with the introduction of GLP-1 pills, showing promising results in clinical trials for effective weight loss and fewer side effects compared to injectables. Analysts predict significant growth in this sector, potentially reaching a market size of $200 billion by 2031.
Investment Opportunities: Several ETFs focused on GLP-1 and weight-loss treatments are available for investors, including Roundhill GLP-1 & Weight Loss ETF (OZEM), Amplify Weight Loss Drug & Treatment ETF (THNR), and GLP-1, Obesity & Cardiometabolic ETF (HRTS), each offering exposure to companies involved in this burgeoning pharmaceutical field.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 59.320
Low
42.00
Averages
54.67
High
70.00
Current: 59.320
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
